Global CRISPR Screening Library Market Strategic Research Report

Scope of the Report

The global CRISPR Screening Library market size is predicted to grow from US$ 213 million in 2025 to US$ 587 million in 2032; it is expected to grow at a CAGR of 15.6% from 2026 to 2032.

CRISPR screening libraries are high-throughput gene perturbation products comprising large sets of designed and quality-controlled guide RNA sequences supplied as vectors, viral particles, synthetic RNA, or other ready-to-use formats. They support gene knockout, interference, activation, or precision editing in cell populations, with phenotypic selection and sequencing used to identify key genes, pathways, and drug targets. Product value is mainly determined by target coverage, guide design quality, library uniformity, off-target control, delivery titer, and compatibility with downstream platforms. The blended gross margin is approximately 55%.

Demand for validated and reproducible functional-genomics evidence is rising across drug research, moving CRISPR screening libraries from specialist academic tools toward routine use in target discovery, mechanism studies, resistance analysis, and cell therapy engineering. Combined workflows that use genome-wide primary screens followed by focused validation screens are supporting growth in both catalog and custom libraries across oncology, immunology, metabolism, and rare-disease research.

Product development is expanding beyond conventional knockout libraries into CRISPR interference, CRISPR activation, base editing, and single-cell perturbation workflows. Suppliers increasingly compete on guide design algorithms, library uniformity, off-target control, viral titer, lot-level quality control, and compatibility with high-content imaging, cell sorting, and single-cell sequencing platforms. Integrated offerings that combine design, construction, packaging, and data analysis are becoming more important.

North America and Europe remain the main markets for premium products and pharmaceutical customers, while demand in China is being supported by innovative drug programs, cell therapy development, and expansion of research platforms. Key risks include cell-model-specific delivery performance, essential-gene bias, insufficient screen coverage, reproducibility, intellectual-property constraints, and biosafety requirements. Opportunities are concentrated in focused libraries, delivery to difficult cell models, single-cell-compatible libraries, and standardized analysis workflows.

Report Scope

This report presents a comprehensive overview of the global CRISPR Screening Library market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• CRISPR Knockout Libraries
• CRISPR Interference Libraries
• CRISPR Activation Libraries
• Base Editing Libraries
• Prime Editing Libraries
• Other CRISPR Screening Libraries

Segment by Guide Count

• Up to 5,000 Guides
• 5,001–25,000 Guides
• 25,001–50,000 Guides
• More than 50,000 Guides

Segment by Library Organization

• Pooled Libraries
• Arrayed Libraries

Segment by Delivery Format

• Oligo Pool Libraries
• Plasmid DNA Libraries
• Lentiviral Particle Libraries
• Synthetic Guide RNA Libraries
• Engineered Cell Libraries

Segment by Application

• Drug Target Discovery and Validation
• Drug Resistance and Sensitivity Screening
• Synthetic Lethality and Combination Therapy
• Functional Genomics and Pathway Analysis
• Immuno-Oncology and Cell Therapy Engineering
• Disease Modeling and Phenotype Screening

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global CRISPR Screening Library market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Drug Target Discovery and Validation, Drug Resistance and Sensitivity Screening, Synthetic Lethality and Combination Therapy evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact